Peptides for women: what the evidence shows

I want to start with something that does not get said enough in peptide content: the research has a major sex bias problem. Most animal studies in this space used male animals. Most early-phase human trials enrolled predominantly male subjects. The assumption was that findings would generalize, which is sometimes true, but is not always true, and we should be honest about when the data applies to women specifically.

With that caveat on the table, here is what the evidence shows for compounds where women's data actually exists.

PT-141 (Bremelanotide): the one FDA-approved specifically for women

PT-141 is the outlier in this list because it is the one compound that was developed specifically with women as the primary population. The RECONNECT phase 3 trials enrolled premenopausal women with hypoactive sexual desire disorder (HSDD), low sexual desire that causes distress.

The mechanism is different from anything else on this list: PT-141 works centrally, activating melanocortin receptors in the brain that are involved in sexual motivation. Not a vascular mechanism, not a hormonal one, directly CNS.

Results from RECONNECT (1,267 women, two phase 3 RCTs): statistically significant improvements in satisfying sexual events and desire scores vs placebo. It got FDA approval in 2019 as Vyleesi. This is the only peptide with a dedicated women's indication and phase 3 RCT data in a female-only population.

The limitation: nausea was common (about 40% of participants), and it caused transient blood pressure increases. It is not for women with cardiovascular disease.

GHK-Cu: the best skin and wound evidence

GHK-Cu is an endogenous tripeptide, your body makes it, it's found in plasma and saliva, and it declines with age. Topical GHK-Cu has the strongest evidence base of any cosmetic peptide I have come across.

A clinical trial by Finkley et al. (2003, Journal of Cosmetic Dermatology) showed topical GHK-Cu improved skin laxity and density vs vehicle control. Multiple other studies support collagen synthesis upregulation and wound healing acceleration. The topical evidence is solid by cosmetic-ingredient standards, which, to be clear, is not the same as pharmaceutical-grade evidence, but it is better than most of what is sold in skincare.

The appeal for women specifically: collagen decline accelerates around menopause due to estrogen loss. GHK-Cu's collagen-stimulating mechanism has obvious relevance there, though I should note that the studies were not specifically conducted in postmenopausal women.

GLP-1 agents: the data includes women

This is where the evidence is strongest, because the STEP and SURMOUNT trial programs for semaglutide and tirzepatide enrolled large mixed-sex populations. The STEP 1 trial was 74% female. SURMOUNT-1 was 64% female. Subgroup analyses show similar efficacy in women vs men.

For women specifically, the metabolic effects of GLP-1 agents have additional relevance in PCOS (polycystic ovary syndrome), where insulin resistance is a central feature. There is a growing body of research on GLP-1 agonists in PCOS, though most is not yet at the scale of the obesity trials.

Epithalon: interesting but thin human data

Epithalon gets mentioned in women's anti-aging contexts because of its proposed telomerase-activating mechanism and the melatonin/circadian connection (the pineal gland it is derived from regulates melatonin, which matters for sleep and hormonal rhythms).

The honest assessment: the human data on Epithalon comes primarily from one Russian research group, sample sizes are small, and there is no sex-stratified analysis that I have found. It is mechanistically interesting. The evidence base for women specifically is essentially nonexistent.

Questions I get asked